IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing.

Z. Paul Lorenc, Jeffrey M. Kenkel, Steven Fagien, Haideh Hirmand, Mark S. Nestor, Anthony P. Sclafani, Jonathan M. Sykes, Heidi A. Waldorf

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

IncobotulinumtoxinA is the third botulinum neurotoxin type A (BoNTA) to be approved for aesthetic use in the United States. This article introduces the new product with an overview of clinical applications and a discussion of the neurotoxin's molecular structure. The role and clinical relevance of complexing proteins in BoNTA products are discussed. Finally, incobotulinumtoxinA's mechanism of action is described.

Original languageEnglish (US)
Pages (from-to)18S-22S
JournalUnknown Journal
Volume33
Issue number1 Suppl
DOIs
StatePublished - Mar 2013

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing.'. Together they form a unique fingerprint.

  • Cite this

    Lorenc, Z. P., Kenkel, J. M., Fagien, S., Hirmand, H., Nestor, M. S., Sclafani, A. P., Sykes, J. M., & Waldorf, H. A. (2013). IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing. Unknown Journal, 33(1 Suppl), 18S-22S. https://doi.org/10.1177/1090820X12474633